JP2015503613A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503613A5 JP2015503613A5 JP2014552154A JP2014552154A JP2015503613A5 JP 2015503613 A5 JP2015503613 A5 JP 2015503613A5 JP 2014552154 A JP2014552154 A JP 2014552154A JP 2014552154 A JP2014552154 A JP 2014552154A JP 2015503613 A5 JP2015503613 A5 JP 2015503613A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- inhibitor
- cancer
- forming component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 81
- 239000003112 inhibitor Substances 0.000 claims 26
- 230000000087 stabilizing effect Effects 0.000 claims 26
- 229920002554 vinyl polymer Polymers 0.000 claims 24
- 239000002202 Polyethylene glycol Substances 0.000 claims 14
- -1 hydroxypropyl Chemical group 0.000 claims 14
- 229920001223 polyethylene glycol Polymers 0.000 claims 14
- 229920001577 copolymer Polymers 0.000 claims 13
- 239000002904 solvent Substances 0.000 claims 13
- 238000004090 dissolution Methods 0.000 claims 10
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 9
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 9
- 239000002105 nanoparticle Substances 0.000 claims 8
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 8
- 229940043355 kinase inhibitor Drugs 0.000 claims 7
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 6
- 239000003909 protein kinase inhibitor Substances 0.000 claims 6
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 5
- 229960001346 nilotinib Drugs 0.000 claims 5
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000004359 castor oil Substances 0.000 claims 4
- 235000019438 castor oil Nutrition 0.000 claims 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
- 229960000984 tocofersolan Drugs 0.000 claims 4
- 239000002076 α-tocopherol Substances 0.000 claims 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 4
- 235000004835 α-tocopherol Nutrition 0.000 claims 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 3
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 3
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 3
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 3
- 229960003005 axitinib Drugs 0.000 claims 3
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960005061 crizotinib Drugs 0.000 claims 3
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 3
- 229960002448 dasatinib Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 229960004891 lapatinib Drugs 0.000 claims 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 3
- 229960000639 pazopanib Drugs 0.000 claims 3
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 229960003787 sorafenib Drugs 0.000 claims 3
- 229960003862 vemurafenib Drugs 0.000 claims 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 150000004922 Dasatinib derivatives Chemical group 0.000 claims 2
- 229910016860 FaSSIF Inorganic materials 0.000 claims 2
- 229910005429 FeSSIF Inorganic materials 0.000 claims 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 2
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims 2
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000024519 eye neoplasm Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229920000609 methyl cellulose Polymers 0.000 claims 2
- 239000001923 methylcellulose Substances 0.000 claims 2
- 235000010981 methylcellulose Nutrition 0.000 claims 2
- 201000008106 ocular cancer Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000002125 Hemangioendothelioma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 210000000270 basal cell Anatomy 0.000 claims 1
- 229960001631 carbomer Drugs 0.000 claims 1
- 229940075508 carbomer homopolymer type b Drugs 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 208000030381 cutaneous melanoma Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000011682 nervous system cancer Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000003708 skin melanoma Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 208000009999 tuberous sclerosis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586187P | 2012-01-13 | 2012-01-13 | |
| US61/586,187 | 2012-01-13 | ||
| SE1250015 | 2012-01-13 | ||
| SE1250015-3 | 2012-01-13 | ||
| US201261713120P | 2012-10-12 | 2012-10-12 | |
| SE1251160-6 | 2012-10-12 | ||
| US61/713,120 | 2012-10-12 | ||
| SE1251160 | 2012-10-12 | ||
| PCT/SE2013/050016 WO2013105895A1 (en) | 2012-01-13 | 2013-01-11 | A pharmaceutical composition comprising stable, amorphous hybrid nanopraticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141912A Division JP6463418B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141910A Division JP6463416B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141913A Division JP6463419B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141911A Division JP6463417B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503613A JP2015503613A (ja) | 2015-02-02 |
| JP2015503613A5 true JP2015503613A5 (enExample) | 2016-02-18 |
| JP6238311B2 JP6238311B2 (ja) | 2017-11-29 |
Family
ID=48781736
Family Applications (14)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552153A Active JP6238310B2 (ja) | 2012-01-13 | 2013-01-11 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2014552154A Active JP6238311B2 (ja) | 2012-01-13 | 2013-01-11 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141911A Active JP6463417B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141912A Active JP6463418B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141910A Active JP6463416B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141913A Active JP6463419B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017160232A Active JP6351810B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2017160233A Active JP6351811B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2017160231A Active JP6351809B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2018107400A Expired - Fee Related JP6628834B2 (ja) | 2012-01-13 | 2018-06-05 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2018246470A Active JP7391507B2 (ja) | 2012-01-13 | 2018-12-28 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2021007043A Expired - Fee Related JP7006995B2 (ja) | 2012-01-13 | 2021-01-20 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2021031869A Active JP7659297B2 (ja) | 2012-01-13 | 2021-03-01 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2023108576A Pending JP2023123773A (ja) | 2012-01-13 | 2023-06-30 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552153A Active JP6238310B2 (ja) | 2012-01-13 | 2013-01-11 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
Family Applications After (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017141911A Active JP6463417B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141912A Active JP6463418B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141910A Active JP6463416B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017141913A Active JP6463419B2 (ja) | 2012-01-13 | 2017-07-21 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2017160232A Active JP6351810B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2017160233A Active JP6351811B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2017160231A Active JP6351809B2 (ja) | 2012-01-13 | 2017-08-23 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2018107400A Expired - Fee Related JP6628834B2 (ja) | 2012-01-13 | 2018-06-05 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2018246470A Active JP7391507B2 (ja) | 2012-01-13 | 2018-12-28 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2021007043A Expired - Fee Related JP7006995B2 (ja) | 2012-01-13 | 2021-01-20 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分を含む安定な非晶質のハイブリッドナノ粒子を製造する方法 |
| JP2021031869A Active JP7659297B2 (ja) | 2012-01-13 | 2021-03-01 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
| JP2023108576A Pending JP2023123773A (ja) | 2012-01-13 | 2023-06-30 | 少なくとも１種のプロテインキナーゼ阻害剤及び少なくとも１種のポリマー性安定化マトリックス形成性成分の安定な非晶質のハイブリッドナノ粒子を含む医薬組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (23) | US20140378454A1 (enExample) |
| EP (7) | EP2802316A4 (enExample) |
| JP (14) | JP6238310B2 (enExample) |
| CN (4) | CN107115317A (enExample) |
| AU (8) | AU2013208324B2 (enExample) |
| CA (2) | CA2860973C (enExample) |
| DK (2) | DK3181122T3 (enExample) |
| ES (2) | ES2946549T3 (enExample) |
| FI (2) | FI3181128T3 (enExample) |
| HR (2) | HRP20230529T1 (enExample) |
| IL (4) | IL293775B2 (enExample) |
| IN (1) | IN2014DN06529A (enExample) |
| MX (4) | MX347456B (enExample) |
| PL (3) | PL2802314T3 (enExample) |
| WO (2) | WO2013105895A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273126B2 (en) | 2017-03-15 | 2022-03-15 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N′-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide |
| US11351123B2 (en) | 2017-03-15 | 2022-06-07 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2946549T3 (es) | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| US9877923B2 (en) | 2012-09-17 | 2018-01-30 | Pfizer Inc. | Process for preparing therapeutic nanoparticles |
| CN104367557A (zh) * | 2013-08-12 | 2015-02-25 | 浙江九洲药业股份有限公司 | 无定型药物活性成分与pvp组合物的制备方法 |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| MX378984B (es) | 2014-03-14 | 2025-03-11 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso. |
| WO2015145145A1 (en) * | 2014-03-24 | 2015-10-01 | Cipla Limited | Pharmaceutical composition comprising lapatinib |
| ZA201502073B (en) * | 2014-03-28 | 2016-03-30 | Cipla Ltd | Pharmaceutical composition |
| JP6554493B2 (ja) | 2014-06-24 | 2019-07-31 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 可溶性生物製剤、治療薬およびイメージング剤をカプセル化するためのプロセス |
| PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
| EP3193877A4 (en) * | 2014-08-07 | 2018-04-04 | Pharmacyclics LLC | Novel formulations of a bruton's tyrosine kinase inhibitor |
| US20170360791A1 (en) * | 2014-12-04 | 2017-12-21 | Astex Pharmaceuticals, Inc. | Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs |
| WO2016097011A1 (en) * | 2014-12-19 | 2016-06-23 | Synthon B.V. | Pharmaceutical composition comprising amorphous nilotinib |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| WO2016154240A1 (en) * | 2015-03-24 | 2016-09-29 | Dow Global Technologies Llc | Aqueous solution of polymers |
| CZ2015250A3 (cs) * | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Amorfní formy vemurafenibu |
| WO2016200688A1 (en) | 2015-06-06 | 2016-12-15 | Cloudbreak Therapeutics, Llc | Compositions and methods for treating pterygium |
| WO2017108605A1 (en) | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous dasatinib |
| US11103461B2 (en) | 2015-12-22 | 2021-08-31 | The Trustees Of Princeton University | Process for encapsulating soluble biologics, therapeutics, and imaging agents |
| CN109475553A (zh) * | 2016-03-17 | 2019-03-15 | 太阳制药工业公司 | 尼洛替尼的药物组合物 |
| KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
| JP6739275B2 (ja) * | 2016-08-02 | 2020-08-12 | 日本化薬株式会社 | ゲフィチニブを有効成分とする医薬組成物 |
| US11491114B2 (en) * | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN110461832A (zh) | 2017-04-06 | 2019-11-15 | 庄信万丰股份有限公司 | 阿法替尼二马来酸盐的新形式 |
| KR102082775B1 (ko) * | 2017-05-02 | 2020-02-28 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
| WO2018203636A1 (ko) * | 2017-05-02 | 2018-11-08 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 조성물 |
| CN107157941B (zh) * | 2017-05-16 | 2020-12-25 | 北京化工大学 | 一种达沙替尼纳米制剂及其制备方法 |
| CN107011262B (zh) * | 2017-06-01 | 2019-10-29 | 中国药科大学 | 一种基于超临界抗溶剂技术制备甲苯磺酸索拉非尼多晶型k微粒的方法 |
| WO2019055539A1 (en) | 2017-09-12 | 2019-03-21 | Prudhomme Robert K | CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME |
| KR102184117B1 (ko) * | 2017-10-31 | 2020-11-30 | 주식회사 삼양바이오팜 | 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법 |
| JP2021501753A (ja) | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿 |
| KR101922369B1 (ko) * | 2018-01-12 | 2018-11-26 | 한국지질자원연구원 | 경구 생체이용률 개선을 위한 약물-층상형 실리케이트 복합체, 이를 포함하는 경구용 약학 조성물 및 상기 복합체의 제조 방법 |
| WO2019195827A1 (en) | 2018-04-06 | 2019-10-10 | Johnson Matthey Public Limited Company | Novel form of ibrutinib |
| WO2019209908A1 (en) | 2018-04-25 | 2019-10-31 | Johnson Matthey Public Limited Company | Crystalline forms of dasatinib |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | KINA INHIBITOR SALTS AND COMPOSITIONS THEREOF |
| WO2019246479A1 (en) | 2018-06-22 | 2019-12-26 | Johnson Matthey Public Limited Company | Form of ponatinib |
| US12186436B2 (en) | 2018-07-19 | 2025-01-07 | The Trustees Of Princeton University | Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents |
| US11731099B2 (en) | 2018-07-20 | 2023-08-22 | The Trustees Of Princeton University | Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation |
| CN109833483B (zh) * | 2018-09-17 | 2020-10-23 | 山东大学 | 基于小分子伴侣的索拉非尼纳米药物的制备 |
| WO2020072870A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Co-crystal forms of baricitinib |
| CN109044977A (zh) * | 2018-10-26 | 2018-12-21 | 武汉工程大学 | 一种乐伐替尼固体分散体及其制备方法和制剂 |
| MX2021004965A (es) * | 2018-11-06 | 2021-06-15 | Beijing Innocare Pharma Tech Co Ltd | Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida. |
| US20200147032A1 (en) | 2018-11-14 | 2020-05-14 | Robert K. Prud'homme | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
| CN113573712A (zh) * | 2019-02-18 | 2021-10-29 | 斯莱班克制药有限责任公司 | 尼洛替尼的药物组合物 |
| US10799459B1 (en) | 2019-05-17 | 2020-10-13 | Xspray Microparticles Ab | Rapidly disintegrating solid oral dosage forms containing dasatinib |
| CN118319863A (zh) * | 2019-09-23 | 2024-07-12 | 生态有限公司 | 治疗制剂及其用途 |
| CN110801434A (zh) * | 2019-10-31 | 2020-02-18 | 金华职业技术学院 | 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法 |
| EP4093379A1 (en) * | 2020-01-24 | 2022-11-30 | Nanocopoeia LLC | Amorphous solid dispersions of dasatinib and uses thereof |
| EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
| EP3861989A1 (en) * | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
| CN112294971B (zh) * | 2020-02-20 | 2022-02-01 | 深圳市泰力生物医药有限公司 | 具有改进的溶解性的尼洛替尼组合物 |
| CN111358952B (zh) * | 2020-04-15 | 2022-03-15 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种抗肿瘤药物组合物及其制剂和应用 |
| CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| CN111467501B (zh) * | 2020-05-22 | 2021-06-15 | 深圳市泰力生物医药有限公司 | 具有改良溶出性质的组合物 |
| CN111973596B (zh) * | 2020-06-15 | 2022-02-15 | 深圳市泰力生物医药有限公司 | 具有改良溶出性质的抗肺纤维化组合物 |
| KR20230044423A (ko) | 2020-07-23 | 2023-04-04 | 크리티테크, 인크. | 라파티닙 입자 및 이의 용도 |
| WO2022034914A1 (ja) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | 易溶性固形製剤およびその製法 |
| US20220047719A1 (en) * | 2020-08-17 | 2022-02-17 | Northwestern University | Enhancing subcutaneous injection and target tissue accumulation of nanoparticles via co-administration with macropinocytosis inhibitory nanoparticles (minp) |
| AU2021353684A1 (en) * | 2020-09-29 | 2023-06-08 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
| CN116234537A (zh) | 2020-10-02 | 2023-06-06 | 隆萨本德公司 | 作为碱性药物的喷雾干燥中的加工助剂的醋酸 |
| EP4032529A4 (en) * | 2020-12-07 | 2022-11-16 | Tianjin Creatron Biotechnology Co., Ltd. | SORAFENIB PHARMACEUTICAL COMPOSITION WITH HIGH BIOAVAILABILITY AND USE THEREOF |
| EP4281047A1 (en) | 2021-01-21 | 2023-11-29 | XSpray Pharma AB (publ) | Fast dissolving pharmaceutical compositions of dasatinib |
| US11980619B2 (en) | 2021-07-28 | 2024-05-14 | Nanocopoeia, Llc | Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses |
| WO2023006029A1 (zh) * | 2021-07-30 | 2023-02-02 | 上海博志研新药物技术有限公司 | 帕唑帕尼口服药物组合物、其制备方法及应用 |
| KR102686558B1 (ko) * | 2022-01-25 | 2024-07-22 | (주)피알지에스앤텍 | 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제 |
| WO2023155182A1 (zh) * | 2022-02-21 | 2023-08-24 | 北京睿创康泰医药研究院有限公司 | 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用 |
| EP4582092A1 (en) * | 2022-10-12 | 2025-07-09 | Chugai Seiyaku Kabushiki Kaisha | Composition containing peptide, surfactant, and polymer |
| KR20240115650A (ko) * | 2023-01-19 | 2024-07-26 | 주식회사 스카이테라퓨틱스 | 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법 |
| EP4658271A1 (en) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Improved cabozantinib compositions and methods of use |
| CN116688139B (zh) * | 2023-06-25 | 2024-03-29 | 深圳市新阳唯康科技有限公司 | 一种克唑替尼药物组合物及其制备方法和应用 |
| CN117100715B (zh) * | 2023-09-05 | 2024-10-15 | 深圳市泰力生物医药有限公司 | 一种含无定型尼洛替尼的胶囊及其制备方法 |
| WO2025099249A1 (en) | 2023-11-08 | 2025-05-15 | Xspray Pharma Ab | Pharmaceutical compositions comprising nilotinib |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| KR102838026B1 (ko) * | 2024-04-30 | 2025-07-28 | 주식회사 스카이테라퓨틱스 | 액시티닙 신규 분자 회합체를 포함하는 점안 조성물 및 이의 제조방법 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9622173D0 (en) * | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| US6406781B1 (en) * | 1998-06-23 | 2002-06-18 | 3M Innovative Properties Company | Stretch release adhesive article with stabilizer |
| GB9920558D0 (en) * | 1999-08-31 | 1999-11-03 | Bradford Particle Design Ltd | Methods for particle formation and their products |
| GB9925934D0 (en) | 1999-11-03 | 1999-12-29 | Glaxo Group Ltd | Novel apparatus and process |
| US20040256749A1 (en) | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| SE0303476D0 (sv) | 2003-12-22 | 2003-12-22 | Censdelivery Ab | Device, method and use for the formation of small particles |
| US7625911B2 (en) * | 2005-01-12 | 2009-12-01 | Mai De Ltd. | Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion |
| EP1885338A1 (en) | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| DE102005053066A1 (de) | 2005-11-04 | 2007-05-10 | Basf Ag | Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen |
| WO2007133750A2 (en) * | 2006-05-12 | 2007-11-22 | The Board Of Trustees Of The Leland Stanford Junior University | Encapsulated nanoparticles for drug delivery |
| CA2654909A1 (en) * | 2006-06-13 | 2007-12-21 | Elan Pharma International Ltd. | Nanoparticulate kinase inhibitor formulations |
| EP2049084A2 (en) * | 2006-07-10 | 2009-04-22 | Elan Pharma International Limited | Nanoparticulate sorafenib formulations |
| EP1920767A1 (en) | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| CA2667720A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| EP2134702B2 (en) | 2007-04-05 | 2023-08-30 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| US7823700B2 (en) * | 2007-07-20 | 2010-11-02 | International Business Machines Corporation | User identification enabled elevator control method and system |
| US8585943B2 (en) | 2007-12-07 | 2013-11-19 | Xspray Microparticles Ab | Method and arrangement for the production of particles |
| JP2009155282A (ja) * | 2007-12-27 | 2009-07-16 | Kowa Co | 固体分散体含有医薬組成物 |
| US20090203709A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| EP2105130A1 (de) | 2008-03-25 | 2009-09-30 | Ratiopharm GmbH | Pharmazeutische Formulierung und Verfahren zu deren Herstellung |
| GB0909154D0 (en) | 2008-09-25 | 2009-07-08 | Nanomaterials Tech Pte Ltd | A process for making particles for delivery of drug nanoparticles |
| US9050317B2 (en) * | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| CZ20098A3 (cs) * | 2009-01-13 | 2010-07-21 | Zentiva, K.S. | Lékové formy inhibitoru tyrosinových kináz |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| KR100924236B1 (ko) * | 2009-06-23 | 2009-10-29 | 충남대학교산학협력단 | 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치 |
| CN103037961A (zh) | 2010-06-14 | 2013-04-10 | X喷雾微粒公司 | 用于生产微粒的装置与方法 |
| EP2616050A1 (en) * | 2010-09-14 | 2013-07-24 | Nanologica AB | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients |
| EP2508174A1 (en) * | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| ES2946549T3 (es) | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| JP2017141910A (ja) * | 2016-02-10 | 2017-08-17 | 武蔵精密工業株式会社 | 伝動装置 |
| JP6688624B2 (ja) * | 2016-02-11 | 2020-04-28 | 学校法人 名城大学 | ガスタンク及びこのガスタンクを複数備えたガスの貯蔵供給設備 |
| JP6767610B2 (ja) * | 2016-02-12 | 2020-10-14 | パナソニックＩｐマネジメント株式会社 | 断熱体とその製造方法 |
| US11590122B2 (en) * | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
-
2013
- 2013-01-11 ES ES17155689T patent/ES2946549T3/es active Active
- 2013-01-11 FI FIEP17155689.7T patent/FI3181128T3/fi active
- 2013-01-11 PL PL13736318T patent/PL2802314T3/pl unknown
- 2013-01-11 CA CA2860973A patent/CA2860973C/en active Active
- 2013-01-11 CN CN201710114340.0A patent/CN107115317A/zh active Pending
- 2013-01-11 DK DK17155686.3T patent/DK3181122T3/da active
- 2013-01-11 EP EP13736055.8A patent/EP2802316A4/en not_active Withdrawn
- 2013-01-11 MX MX2014008457A patent/MX347456B/es active IP Right Grant
- 2013-01-11 CN CN201710114342.XA patent/CN107115318A/zh active Pending
- 2013-01-11 PL PL17155689.7T patent/PL3181128T3/pl unknown
- 2013-01-11 JP JP2014552153A patent/JP6238310B2/ja active Active
- 2013-01-11 HR HRP20230529TT patent/HRP20230529T1/hr unknown
- 2013-01-11 AU AU2013208324A patent/AU2013208324B2/en active Active
- 2013-01-11 CA CA2860932A patent/CA2860932C/en active Active
- 2013-01-11 ES ES17155686T patent/ES2946735T3/es active Active
- 2013-01-11 CN CN201380012196.XA patent/CN104159574A/zh active Pending
- 2013-01-11 AU AU2013208323A patent/AU2013208323B2/en not_active Ceased
- 2013-01-11 US US14/371,843 patent/US20140378454A1/en not_active Abandoned
- 2013-01-11 DK DK17155689.7T patent/DK3181128T3/da active
- 2013-01-11 IL IL293775A patent/IL293775B2/en unknown
- 2013-01-11 EP EP17155689.7A patent/EP3181128B1/en active Active
- 2013-01-11 WO PCT/SE2013/050016 patent/WO2013105895A1/en not_active Ceased
- 2013-01-11 EP EP13736318.0A patent/EP2802314B1/en active Active
- 2013-01-11 PL PL17155686.3T patent/PL3181122T3/pl unknown
- 2013-01-11 EP EP23159964.8A patent/EP4218740A1/en active Pending
- 2013-01-11 IN IN6529DEN2014 patent/IN2014DN06529A/en unknown
- 2013-01-11 HR HRP20230510TT patent/HRP20230510T1/hr unknown
- 2013-01-11 EP EP17155686.3A patent/EP3181122B1/en active Active
- 2013-01-11 EP EP17155688.9A patent/EP3181127B1/en active Active
- 2013-01-11 IL IL293779A patent/IL293779B2/en unknown
- 2013-01-11 WO PCT/SE2013/050015 patent/WO2013105894A1/en not_active Ceased
- 2013-01-11 JP JP2014552154A patent/JP6238311B2/ja active Active
- 2013-01-11 US US14/371,875 patent/US9456992B2/en active Active
- 2013-01-11 EP EP20194223.2A patent/EP3766486A1/en not_active Withdrawn
- 2013-01-11 FI FIEP17155686.3T patent/FI3181122T3/fi active
- 2013-01-11 CN CN201380011957.XA patent/CN104159577B/zh active Active
-
2014
- 2014-07-10 MX MX2022003458A patent/MX2022003458A/es unknown
- 2014-07-10 MX MX2020000984A patent/MX2020000984A/es unknown
- 2014-07-10 MX MX2023008180A patent/MX2023008180A/es unknown
- 2014-07-10 IL IL233583A patent/IL233583B/en active IP Right Grant
- 2014-07-10 IL IL233582A patent/IL233582B/en unknown
-
2016
- 2016-05-13 US US15/153,807 patent/US20160250153A1/en not_active Abandoned
- 2016-08-26 US US15/248,107 patent/US9827230B2/en active Active
-
2017
- 2017-02-02 US US15/423,136 patent/US9833442B2/en active Active
- 2017-02-02 US US15/423,183 patent/US9833443B2/en active Active
- 2017-07-21 JP JP2017141911A patent/JP6463417B2/ja active Active
- 2017-07-21 JP JP2017141912A patent/JP6463418B2/ja active Active
- 2017-07-21 JP JP2017141910A patent/JP6463416B2/ja active Active
- 2017-07-21 JP JP2017141913A patent/JP6463419B2/ja active Active
- 2017-08-23 JP JP2017160232A patent/JP6351810B2/ja active Active
- 2017-08-23 JP JP2017160233A patent/JP6351811B2/ja active Active
- 2017-08-23 JP JP2017160231A patent/JP6351809B2/ja active Active
- 2017-10-23 US US15/791,093 patent/US10143683B2/en active Active
-
2018
- 2018-02-08 AU AU2018200928A patent/AU2018200928B2/en active Active
- 2018-02-08 AU AU2018200931A patent/AU2018200931B2/en active Active
- 2018-02-08 AU AU2018200933A patent/AU2018200933B2/en active Active
- 2018-06-05 JP JP2018107400A patent/JP6628834B2/ja not_active Expired - Fee Related
- 2018-10-29 US US16/173,466 patent/US10314829B2/en active Active
- 2018-10-31 US US16/176,101 patent/US10314830B2/en active Active
- 2018-12-28 JP JP2018246470A patent/JP7391507B2/ja active Active
-
2019
- 2019-05-06 US US16/404,004 patent/US10561644B2/en active Active
- 2019-05-06 US US16/404,027 patent/US10555937B2/en active Active
- 2019-05-06 US US16/403,969 patent/US10561643B2/en active Active
- 2019-05-06 US US16/404,059 patent/US10561645B2/en active Active
- 2019-12-02 AU AU2019275513A patent/AU2019275513B2/en active Active
-
2020
- 2020-02-07 US US16/784,498 patent/US10772877B2/en active Active
- 2020-08-18 US US16/995,880 patent/US11241419B2/en active Active
-
2021
- 2021-01-20 JP JP2021007043A patent/JP7006995B2/ja not_active Expired - Fee Related
- 2021-03-01 JP JP2021031869A patent/JP7659297B2/ja active Active
- 2021-11-16 AU AU2021269331A patent/AU2021269331B2/en active Active
- 2021-11-16 AU AU2021269328A patent/AU2021269328B2/en active Active
- 2021-12-16 US US17/552,768 patent/US11963951B2/en active Active
-
2022
- 2022-02-14 US US17/671,157 patent/US11426391B2/en active Active
- 2022-02-14 US US17/671,207 patent/US11376243B2/en active Active
- 2022-06-01 US US17/829,736 patent/US11517562B2/en active Active
-
2023
- 2023-06-30 JP JP2023108576A patent/JP2023123773A/ja active Pending
-
2024
- 2024-01-12 US US18/411,773 patent/US12076314B2/en active Active
- 2024-07-22 US US18/779,499 patent/US12144804B1/en active Active
- 2024-08-15 US US18/805,904 patent/US20240398769A1/en active Pending
- 2024-12-02 US US18/964,814 patent/US20250090511A1/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273126B2 (en) | 2017-03-15 | 2022-03-15 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[N′-(2-chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide |
| US11351123B2 (en) | 2017-03-15 | 2022-06-07 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide |
| US12194153B2 (en) | 2017-03-15 | 2025-01-14 | Sun Pharma Advanced Research Company Limited | Amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n′-(2-chloro-6-methyl-benzoyl) hydrazide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503613A5 (enExample) | ||
| ES2935800T3 (es) | Forma de dosificación oral de ketamina | |
| CA2856646C (en) | Combination treatment of cancer | |
| JP2014512356A5 (enExample) | ||
| HRP20230510T1 (hr) | Farmaceutski pripravak dasatinib | |
| RU2684632C2 (ru) | Аморфная твердая дисперсия, содержащая таксан, таблетка, содержащая такую дисперсию, и способ их получения | |
| JP2018109022A5 (enExample) | ||
| JP2014509659A5 (enExample) | ||
| JP2014512354A5 (enExample) | ||
| TW201720833A (zh) | 用於治療癌症的四環喹諾酮類似物組合療法 | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| CN102036656A (zh) | 含有蜡的缓释制剂 | |
| JP7522661B2 (ja) | ビスフルオロアルキル－１，４－ベンゾジアゼピノン化合物を含む組み合わせ組成物およびその使用方法 | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| BR112014011981B1 (pt) | FORMULAgOES FARMACEUTICAS SOLIDAS ORAIS, SEUS PROCESSOS DE PREPARAgAO E USOS | |
| JP2016529285A5 (enExample) | ||
| JP2015501808A5 (enExample) | ||
| TWI544920B (zh) | Ｎ－羥基－４－｛２－［３－（ｎ，ｎ－二甲基胺基甲基）苯並呋喃－２－基羰基胺基］乙氧基｝苯甲醯胺之新穎投藥法 | |
| CN114209702A (zh) | 尼洛替尼的药物组合物 | |
| CA3034875C (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| WO2012087257A2 (en) | Oral dosage form comprising imatinib and production of said oral dosage form | |
| CN103491952A (zh) | 用于治疗癌症的新颖联合疗法 | |
| CN102958514B (zh) | 口腔内崩解片剂 | |
| WO2017118401A1 (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JP2019503353A (ja) | 非晶質オナプリストン組成物およびそれを作製する方法 |